0000885725-15-000022.txt : 20151028 0000885725-15-000022.hdr.sgml : 20151028 20151028063238 ACCESSION NUMBER: 0000885725-15-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20151028 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151028 DATE AS OF CHANGE: 20151028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 151179007 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 q32015erform8-k.htm 8-K: Q3 2015 EARNINGS RELEASE 8-K



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
_____________________________________________________________________


FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 
______________________________________________________________________

Date of Report (Date of earliest event reported): October 28, 2015

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)


DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
 
 


300 Boston Scientific Way, Marlborough, Massachusetts
01752-1234
(Address of principal executive offices)
(Zip code)

Registrant's telephone number, including area code:   (508) 683-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On October 28, 2015, Boston Scientific Corporation issued a press release announcing financial results for the third quarter ended September 30, 2015. A copy of the release is furnished with this report as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.


ITEM 9.01.     FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits


Exhibit No.        Description

99.1        Press Release issued by Boston Scientific Corporation dated October 28, 2015





SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                

Date:
October 28, 2015
BOSTON SCIENTIFIC CORPORATION
 
 
 
 
 
 
By:
/s/ Vance R. Brown
 
 
 
Vance R. Brown
 
 
 
Vice President and Chief Corporate Counsel





INDEX TO EXHIBITS
 

Exhibit  No.
 Description
 
99.1
 Press Release issued by Boston Scientific Corporation dated
October 28, 2015

 




 EX-99.1 2 pressreleaseq32015.htm EXHIBIT 99.1 - PRESS RELEASE ISSUED OCTOBER 28, 2015 Exhibit




FOR IMMEDIATE RELEASE

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR
THIRD QUARTER 2015


Marlborough, Mass. (October 28, 2015) -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.888 billion during the third quarter ended September 30, 2015, compared to the company's guidance range for the quarter of $1.790 to $1.840 billion. This represents 9 percent operational revenue growth (constant currency basis, excluding divested businesses) and an increase of 2 percent on a reported basis, all compared to the prior year period. The company achieved adjusted earnings per share of $0.24 for the period, compared to $0.20 a year ago, and reported a GAAP loss of $198 million, or $(0.15) per share, compared to earnings of $0.03 a year ago.

"Our excellent third quarter performance was driven by strong sales and differentiated adjusted operating margin expansion," said Mike Mahoney, president and chief executive officer, Boston Scientific. "Our global teams continue to advance our mission to transform the lives of patients through innovative medical solutions. In this quarter, we launched several exciting products, invested in multiple early-stage companies and began the important work of integrating the AMS male urology portfolio into Boston Scientific."

Third quarter financial results and recent developments:

•
Reported third quarter sales of $1.888 billion, representing 9 percent operational revenue growth and an increase of 2 percent on a reported basis, all compared to the prior year period.

•
Achieved 5 percent organic revenue growth. Organic revenue growth excludes the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisitions of the interventional business of Bayer AG (Bayer) and the American Medical Systems (AMS) male urology portfolio over the prior year period.

•
Delivered adjusted earnings per share of $0.24 compared to the company's guidance range of $0.21 to $0.23 per share, and reported a GAAP loss of $(0.15) per share compared to the company’s guidance range of $0.10 to $0.13 per share, primarily due to litigation-related charges.

•
Achieved third quarter revenue growth of 17 percent in MedSurg (8 percent organic), 9 percent in Cardiovascular (6 percent organic) and 2 percent in Rhythm Management (2 percent organic), all on a constant currency basis over the prior year period.





•
Delivered strong operational revenue growth across all three major regions. Achieved 10 percent growth in the U.S. (4 percent organic) and 9 percent growth (7 percent organic) in both Europe and AMEA (Asia, Middle East and Africa), all on a constant currency basis over the prior year period. Delivered 13 percent operational and organic revenue growth in Emerging Markets.

•
Gained Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System, creating a new category of coronary drug-eluting stents, and received Investigational Device Exemption for the EVOLVE Short Dual Anti-Platelet Therapy study.

•
Announced 12-month data from the MAJESTIC trial demonstrating the strong safety profile and primary patency rate* (of more than 96 percent) of the Eluvia™ Drug-Eluting Vascular Stent System.

•
Received FDA approval of the Innova™ Vascular Self-Expanding Stent System to treat patients with peripheral artery disease.

•
Gained CE mark for MRI-compatible labeling for the current family of Extended Longevity and MINI implantable cardioverter defibrillator systems** and the X4 cardiac resynchronization therapy defibrillator systems**, enabling patients implanted with these devices to safely undergo MRI diagnostics.

•
Received CE mark for the Vercise™ Primary Cell Deep Brain Stimulation System**, including the first directional lead with current steering and expanded programming flexibility.

•
Announced strategic alliance with Preventice Solutions to expand the Boston Scientific portfolio of remote monitoring solutions.

•
Closed acquisition of the AMS male urology portfolio from Endo International plc, further strengthening Boston Scientific's leadership in urology and pelvic health.




* Primary patency defined as duplex ultrasound peak systolic velocity ratio ≤ 2.5 and absence of TLR or bypass; data reflect actual values (not Kaplan Meier estimates).

** Investigational device and not available for sale in the U.S. CE-marked device, available for sale in CE-mark countries. 







Worldwide sales for the third quarter:
 
 
 
 
 
Change
 
 
Three Months Ended
September 30,
 
As Reported Basis
 
Less: Impact of Foreign Currency
 
Constant Currency Basis
in millions
2015
2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Interventional Cardiology
$
500

$
508

 
(2
)
%
 
$
(45
)
(9
)
%
 
7

%
 
   Peripheral Interventions
227

215

 
6

%
 
(17
)
(7
)
%
 
13

%
 
Cardiovascular
727

723

 
0

%
 
(62
)
(9
)
%
 
9

%
 
   Cardiac Rhythm Management
451

480

 
(6
)
%
 
(30
)
(6
)
%
 
0

%
 
   Electrophysiology
57

54

 
6

%
 
(4
)
(7
)
%
 
13

%
 
Rhythm Management
508

534

 
(5
)
%
 
(34
)
(7
)
%
 
2

%
 
   Endoscopy
331

336

 
(1
)
%
 
(27
)
(8
)
%
 
7

%
 
   Urology and Pelvic Health
198

137

 
44

%
 
(8
)
(6
)
%
 
50

%
 
   Neuromodulation
124

115

 
8

%
 
(4
)
(3
)
%
 
11

%
 
MedSurg
653

588

 
11

%
 
(39
)
(6
)
%
 
17

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subtotal Core Businesses
1,888

1,845

 
2

%
 
(135
)
(7
)
%
 
9

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Divested Businesses
—

1

 
N/A

 
 
—

N/A

 
 
N/A

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Worldwide Net Sales
$
1,888

$
1,846

 
2

%
 
$
(135
)
(7
)
%
 
9

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.
 
Sales growth rates that exclude the impact of sales from divested businesses and/or changes in foreign currency exchange rates are not prepared in accordance with U.S. GAAP. An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release.

On a consolidated GAAP basis, net loss for the third quarter of 2015 was $198 million, or $(0.15) per share. These results included intangible asset impairment charges, acquisition- and divestiture-, litigation-, restructuring and restructuring- related net charges, pension termination charges and amortization expense, of $524 million (after-tax) or $0.39 per share. Adjusted net income for the third quarter of 2015, excluding these net charges, was $326 million, or $0.24 per share.

On a consolidated GAAP basis, net income for the third quarter of 2014 was $43 million, or $0.03 per share. These results included intangible asset impairment charges, acquisition- and divestiture-, litigation-, restructuring and restructuring -related net charges, and amortization expense, of $230 million (after-tax) or $0.17 per share. Adjusted net income for the third quarter of 2014, excluding these net charges, was $273 million, or $0.20 per share.





Guidance for Full Year and Fourth Quarter 2015

The company now estimates revenue for the full year 2015 to be in a range of $7.470 to $7.510 billion (compared to prior guidance of $7.275 to $7.375 billion), which versus the prior year period represents growth of approximately 1 to 2 percent on a reported basis and growth of approximately 8 percent on an operational basis. The company now estimates income on a GAAP basis in a range of $0.02 to $0.05 per share (compared to prior guidance of $0.28 to $0.34 per share), and now estimates adjusted earnings, excluding intangible asset impairment charges, debt extinguishment charges, acquisition- and divestiture-, litigation-, and restructuring-related net charges, pension termination charges, and amortization expense, in a range of $0.90 to $0.92 per share (compared to $0.88 to $0.92 per share).

The company estimates sales for the fourth quarter of 2015 in a range of $1.970 to $2.010 billion. The company estimates earnings on a GAAP basis in a range of $0.10 to $0.13 per share. Adjusted earnings, excluding acquisition- and divestiture- and restructuring-related net charges and amortization expense, are estimated in a range of $0.23 to $0.25 per share.

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. (ET). The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP and operational revenue growth rates, GAAP earnings and adjusted earnings for the fourth quarter and full year 2015; our financial performance; our business plans; and our positioning for revenue and earnings growth.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which




we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this press release.

Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this news release.

 
CONTACT:
 
Media:
Kelly Leadem
 
508-683-5543 (office)
 
Media Relations
 
Boston Scientific Corporation
 
kelly.leadem@bsci.com
Investors:
Susan Lisa, CFA
 
508-683-5565 (office)
 
Investor Relations
 
Boston Scientific Corporation
 
investor_relations@bsci.com






BOSTON SCIENTIFIC CORPORATION
CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS
(Unaudited)

 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
in millions, except per share data
2015
2014
 
2015
2014
 
 
 
 
 
 
Net sales
$
1,888

$
1,846

 
$
5,499

$
5,493

Cost of products sold
539

550

 
1,600

1,651

Gross profit
1,349

1,296

 
3,899

3,842

 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
Selling, general and administrative expenses
729

741

 
2,095

2,150

Research and development expenses
221

212

 
632

609

Royalty expense
17

21

 
53

86

Amortization expense
131

109

 
361

327

Intangible asset impairment charges
10

12

 
19

177

Contingent consideration expense (benefit)
40

(4
)
 
86

(122
)
Restructuring charges
7

2

 
16

37

Litigation-related charges (credits)
457

139

 
649

399

Pension termination charges
36

—

 
44

—

Gain on divestiture
—

—

 
—

(12
)
 
1,648

1,232

 
3,955

3,651

Operating income (loss)
(299
)
64

 
(56
)
191

 
 
 
 
 
 
Other income (expense):
 
 
 
 
 
Interest expense
(58
)
(54
)
 
(225
)
(161
)
Other, net
(10
)
(7
)
 
(31
)
15

Income (loss) before income taxes
(367
)
3

 
(312
)
45

Income tax expense (benefit)
(169
)
(40
)
 
(215
)
(135
)
Net income (loss)
$
(198
)
$
43

 
$
(97
)
$
180

 
 
 
 
 
 
Net income (loss) per common share - basic
$
(0.15
)
$
0.03

 
$
(0.07
)
$
0.14

Net income (loss) per common share - assuming dilution
$
(0.15
)
$
0.03

 
$
(0.07
)
$
0.13

 
 
 
 
 
 
Weighted-average shares outstanding
 
 
 
 
 
Basic
1,344.0

1,325.5

 
1,339.7

1,323.5

Assuming dilution
1,344.0

1,347.6

 
1,339.7

1,347.3







BOSTON SCIENTIFIC CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
 
As of
 
September 30,
 
December 31,
in millions, except share data
2015
 
2014
 
(Unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
350

 
$
587

Trade accounts receivable, net
1,274

 
1,183

Inventories
1,086

 
946

Deferred and prepaid income taxes
367

 
447

Other current assets
385

 
443

Total current assets
3,462

 
3,606

 
 
 
 
Property, plant and equipment, net
1,479

 
1,507

Goodwill
6,468

 
5,898

Other intangible assets, net
6,228

 
5,606

Other long-term assets
578

 
425

TOTAL ASSETS
$
18,215

 
$
17,042

 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Current debt obligations
$
63

 
$
403

Accounts payable
210

 
262

Accrued expenses
1,605

 
1,950

Other current liabilities
360

 
231

Total current liabilities
2,238

 
2,846

 
 
 
 
Long-term debt
5,796

 
3,859

Deferred income taxes
770

 
1,214

Other long-term liabilities
3,001

 
2,666

 
 
 
 
Commitments and contingencies
 
 
 
 
 
 
 
Stockholders' equity
 
 
 
Preferred stock, $.01 par value - authorized 50,000,000 shares,
 
 
 
 none issued and outstanding
 
 
 
Common stock, $.01 par value - authorized 2,000,000,000 shares -
 
 
 
 issued 1,592,429,606 shares as of September 30, 2015 and
 
 
 
1,575,018,236 shares as of December 31, 2014
16

 
16

Treasury stock, at cost - 247,566,270 shares as of September 30, 2015
 
 
 
and 247,566,270 shares as of December 31, 2014
(1,717
)
 
(1,717
)
Additional paid-in capital
16,815

 
16,703

Accumulated deficit
(8,785
)
 
(8,689
)
Accumulated other comprehensive income (loss), net of tax
81

 
144

Total stockholders' equity
6,410

 
6,457

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
18,215

 
$
17,042





BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)
 
 
Three Months Ended September 30, 2015
 
in millions, except per share data
 
Pre-Tax
 
Tax
Impact (a)
 
After-Tax
 
Impact per Share
 
GAAP net income (loss)
 
$
(367
)
 
$
169

 
$
(198
)
 
$
(0.15
)
 
Non-GAAP adjustments:
 
 
 
 
 
  
 
 
 
Intangible asset impairment charges
 
10

 
(1
)
 
9

 
0.01

*
Acquisition- and divestiture-related net charges (b)
 
80

 
(12
)
 
68

 
0.05

*
Restructuring and restructuring-related net charges (c)
 
21

 
(3
)
 
18

 
0.01

*
Litigation-related net charges
 
457

 
(165
)
 
292

 
0.22

*
Pension termination charges
 
36

 
(13
)
 
23

 
0.02

*
Amortization expense
 
131

 
(17
)
 
114

 
0.08

*
Adjusted net income
 
$
368

 
$
(42
)
 
$
326

 
$
0.24

 
 
 
 
 
 
 
 
 
 
 
*Assumes dilution of 20.2 million shares for the three months ended September 30, 2015 for all or a portion of these non-GAAP Adjustments
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended September 30, 2014
 
in millions, except per share data
 
Pre-Tax
 
Tax
Impact (a)
 
After-Tax
 
Impact per Share
 
GAAP net income (loss)
 
$
3

 
$
40

 
$
43

 
$
0.03

 
Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
Intangible asset impairment charges
 
12

 
(2
)
 
10

 
0.01

 
Acquisition- and divestiture-related net charges (d)
 
38

 
(15
)
 
23

 
0.02

 
Restructuring and restructuring-related net charges (e)
 
17

 
(3
)
 
14

 
0.01

 
Litigation-related net charges
 
139

 
(50
)
 
89

 
0.06

 
Amortization expense
 
109

 
(15
)
 
94

 
0.07

 
Adjusted net income
 
$
318

 
$
(45
)
 
$
273

 
$
0.20

 
 
 
 
 
 
 
 
 
 
 
(a) Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."
 
(b) In the third quarter of 2015, pre-tax acquisition- and divestiture-related net charges were $80 million, of which $16 million was recorded in cost of products sold, $23 million was recorded in selling, general and administrative expenses, $1 million was recorded in research and development, and $40 million was recorded as contingent consideration expense.
 
(c) In the third quarter of 2015, pre-tax restructuring charges were $7 million and pre-tax restructuring- related charges were $14 million, of which $5 million was recorded in cost of products sold and $9 million was recorded in selling, general and administrative expenses.
 
(d) In the third quarter of 2014, pre-tax acquisition- and divestiture-related net charges were $38 million, of which charges of $8 million were recorded in cost of products sold, charges of $34 million were recorded in selling, general and administrative expenses and $4 million was recorded as a contingent consideration benefit.
 
(e) In the third quarter of 2014, pre-tax restructuring charges were $2 million and pre-tax restructuring- related charges were $15 million, of which $9 million was recorded in cost of products sold and $6 million was recorded in selling, general and administrative expenses.
 
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.
 







BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)
 
 
Nine Months Ended September 30, 2015
 
in millions, except per share data
 
Pre-Tax
 
Tax
Impact (a)
 
After-Tax
 
Impact per Share
 
GAAP net income (loss)
 
$
(312
)
 
$
215

 
$
(97
)
 
$
(0.07
)
 
Non-GAAP adjustments:
 
 
 
 
 
  
 
 
 
Intangible asset impairment charges
 
19

 
(3
)
 
16

 
0.01

*
Acquisition- and divestiture-related net charges (b)
 
169

 
(17
)
 
152

 
0.11

*
Restructuring and restructuring-related net charges (c)
 
58

 
(10
)
 
48

 
0.04

*
Litigation-related net charges
 
649

 
(235
)
 
414

 
0.31

*
Pension termination charges
 
44

 
(16
)
 
28

 
0.02

*
Debt extinguishment charges (d)
 
45

 
(16
)
 
29

 
0.02

*
Amortization expense
 
361

 
(46
)
 
315

 
0.23

*
Adjusted net income
 
$
1,033

 
$
(128
)
 
$
905

 
$
0.67

 
 
 
 
 
 
 
 
 
 
 
*Assumes dilution of 21.5 million shares for the nine months ended September 30, 2015 for all or a portion of these non-GAAP Adjustments
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2014
 
in millions, except per share data
 
Pre-Tax
 
Tax
Impact (a)
 
After-Tax
 
Impact per Share
 
GAAP net income (loss)
 
$
45

 
$
135

 
$
180

 
$
0.13

 
Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
Intangible asset impairment charges
 
177

 
(27
)
 
150

 
0.11

 
Acquisition- and divestiture-related net credits (e)
 
(80
)
 
(16
)
 
(96
)
 
(0.07
)
 
Restructuring and restructuring-related net charges (f)
 
70

 
(16
)
 
54

 
0.04

 
Litigation-related net charges
 
399

 
(149
)
 
250

 
0.19

 
Amortization expense
 
327

 
(39
)
 
288

 
0.21

 
Adjusted net income
 
$
938

 
$
(112
)
 
$
826

 
$
0.61

 
 
 
 
 
 
 
 
 
 
 
(a) Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."
 
(b) In the first nine months of 2015, pre-tax acquisition- and divestiture-related net charges were $169 million, of which $24 million was recorded in cost of products sold, $36 million was recorded in selling, general and administrative expenses, $19 million was recorded in research and development, $86 million was recorded as contingent consideration expense, and $4 million was recorded as interest expense.
 
(c) In the first nine months of 2015, pre-tax restructuring charges were $16 million and pre-tax restructuring- related charges were $42 million, of which $20 million was recorded in cost of products sold and $22 million was recorded in selling, general and administrative expenses.
 
(d) Debt extinguishment charges are recorded in interest expense.
 
(e) In the first nine months of 2014, pre-tax acquisition- and divestiture-related net credits were $80 million, of which charges of $13 million were recorded in cost of products sold, charges of $60 million were recorded in selling, general and administrative expenses, $122 million was recorded as a contingent consideration benefit, $12 million was recorded as a gain on divestiture and $19 million was recorded as gains on previously held equity interests within Other, net.
 
(f) In the first nine months of 2014, pre-tax restructuring charges were $37 million and pre-tax restructuring- related charges were $33 million, of which $15 million was recorded in cost of products sold and $18 million was recorded in selling, general and administrative expenses.
 
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.
 






BOSTON SCIENTIFIC CORPORATION
SEGMENT INFORMATION
(Unaudited)
SEGMENT NET SALES*
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
in millions
 
2015
 
2014
 
Change
 
2015
 
2014
 
Change
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Interventional Cardiology
 
$
551

 
$
514

 
7

%
 
$
1,659

 
$
1,543

 
7

%
        Peripheral Interventions
 
246

 
217

 
13

%
 
723

 
631

 
15

%
Cardiovascular
 
797

 
731

 
9

%
 
2,382

 
2,174

 
9

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Cardiac Rhythm Management
 
483

 
482

 
0

%
 
1,456

 
1,441

 
1

%
        Electrophysiology
 
61

 
54

 
13

%
 
182

 
167

 
9

%
Rhythm Management
 
544

 
536

 
2

%
 
1,638

 
1,608

 
2

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Endoscopy
 
362

 
340

 
7

%
 
1,042

 
990

 
6

%
        Urology and Pelvic Health
 
207

 
138

 
50

%
 
479

 
397

 
21

%
        Neuromodulation
 
128

 
115

 
11

%
 
369

 
338

 
8

%
MedSurg
 
697

 
593

 
17

%
 
1,890

 
1,725

 
10

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subtotal Core Businesses
 
2,038

 
1,860

 
9

%
 
5,910

 
5,507

 
7

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Divested Businesses
 
—

 
1

 
N/A

 
 
—

 
4

 
N/A

 
Foreign Currency
 
(150
)
 
(15
)
 
N/A

 
 
(411
)
 
(18
)
 
N/A

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Worldwide Net Sales
 
$
1,888

 
$
1,846

 
9

%
 
$
5,499

 
$
5,493

 
7

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

SEGMENT OPERATING INCOME*
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
in millions
 
2015
 
2014
 
2015
 
2014
 
 
 
 
 
 
 
 
 
Segment operating income
 
 
 
 
 
 
 
 
Cardiovascular
 
$
249

 
$
201

 
$
732

 
$
565

Rhythm Management
 
97

 
76

 
252

 
209

MedSurg
 
235

 
192

 
590

 
535

Operating income allocated to reportable segments
 
581

 
469

 
1,574

 
1,309

Corporate expenses and currency exchange
 
(145
)
 
(90
)
 
(334
)
 
(205
)
Intangible asset impairment charges; pension termination charges; acquisition-, divestiture-, restructuring-, and litigation-related net charges and credits
 
(604
)
 
(206
)
 
(935
)
 
(586
)
Amortization expense
 
(131
)
 
(109
)
 
(361
)
 
(327
)
Operating income (loss)
 
$
(299
)
 
$
64

 
$
(56
)
 
$
191

 
 
 
 
 
 
 
 
 
*We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency and sales from divested businesses. Sales generated from reportable segments and divested businesses, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to intangible asset impairment charges; acquisition and divestiture-, restructuring- and litigation-related net charges and credits; pension termination charges; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation above.





BOSTON SCIENTIFIC CORPORATION
WORLDWIDE CARDIAC RHYTHM MANAGEMENT (CRM) SALES
(Unaudited)


Three Months Ended September 30
in millions
 
U.S.
 
International
 
Worldwide
 
 
Q3 2015
Q3 2014
 
Q3 2015
Q3 2014
 
Q3 2015
Q3 2014
      Defibrillator systems
 
$
216

$
222

 
$
110

$
126

 
$
326

$
348

      Pacemaker systems
 
63

64

 
62

68

 
125

132

Total CRM products
 
$
279

$
286

 
$
172

$
194

 
$
451

$
480


Nine Months Ended September 30
in millions
 
U.S.
 
International
 
Worldwide
 
 
YTD 2015
YTD 2014
 
YTD 2015
YTD 2014
 
YTD 2015
YTD 2014
      Defibrillator systems
 
$
655

$
653

 
$
341

$
389

 
$
996

$
1,042

      Pacemaker systems
 
181

194

 
190

208

 
371

402

Total CRM products
 
$
836

$
847

 
$
531

$
597

 
$
1,367

$
1,444







BOSTON SCIENTIFIC CORPORATION
SEGMENT AND REGIONAL NET SALES
(Unaudited)



Q3 2015 Segment Net Sales as compared to Q3 2014
 
MedSurg
Cardiovascular
Rhythm Management
Total BSC
Percentage change in net sales, as reported
11
 %
0
 %
(5
)%
2
 %
Less: Impact of Foreign Currency Fluctuations
(6
)%
(9
)%
(7
)%
(7
)%
Percentage change in net sales, constant currency
17
 %
9
 %
2
 %
9
 %
Less: Impact of AMS and Bayer acquisitions
9
 %
3
 %
0
 %
4
 %
Percentage change in net sales, organic
8
 %
6
 %
2
 %
5
 %


Q3 2015 Regional Net Sales as compared to Q3 2014
 
U.S.
Europe
AMEA
Emerging Markets*
Percentage change in net sales, as reported
10
%
(8
)%
(3
)%
0
 %
Less: Impact of Foreign Currency Fluctuations
—
%
(17
)%
(12
)%
(13
)%
Percentage change in net sales, constant currency
10
%
9
 %
9
 %
13
 %
Less: Impact of AMS and Bayer acquisitions
6
%
2
 %
2
 %
0
 %
Percentage change in net sales, organic
4
%
7
 %
7
 %
13
 %


*We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors, and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets.

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.





BOSTON SCIENTIFIC CORPORATION
ESTIMATED NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)


Q4 and Full Year 2015 EPS Guidance

 
Q4 2015 Estimate
 
Full Year 2015 Estimate
 
Prior Full Year 2015 Estimate
 
(Low)
(High)
 
(Low)
(High)
 
(Low)
(High)
GAAP results
$
0.10

$
0.13

 
$
0.02

$
0.05

 
$
0.28

$
0.34

 
 
 
 
 
 
 
 
 
Intangible asset impairment charges
—

—

 
0.01

0.01

 
0.01

0.01

Debt extinguishment charges
—

—

 
0.02

0.02

 
0.02

0.02

Estimated acquisition and divestiture-related net charges
0.03

0.02

 
0.14

0.13

 
0.10

0.09

Estimated restructuring-related charges
0.02

0.02

 
0.06

0.06

 
0.06

0.06

Estimated amortization expense
0.08

0.08

 
0.32

0.32

 
0.29

0.29

Estimated pension termination charges
—

—

 
0.02

0.02

 
0.03

0.02

Litigation-related charges
—

—

 
0.31

0.31

 
0.09

0.09

 
 
 
 
 
 
 
 
 
Adjusted results
$
0.23

$
0.25

 
$
0.90

$
0.92

 
$
0.88

$
0.92

 
 
 
 
 
 
 
 
 

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.


Use of Non-GAAP Financial Measures

To supplement our financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income and adjusted net income per share that exclude certain amounts, and revenue growth rates that exclude the impact of sales from divested businesses, changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.

The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate revenue growth rates that exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this non-GAAP financial measure and the non-GAAP financial measures that excludes sales from divested businesses and/or the impacts of recent acquisitions with significant sales is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. With the exception of the impact of recent acquisitions with significant sales, the adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures




that are reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income and adjusted net income per share that exclude certain amounts, and revenue growth rates that exclude the impact of sales from divested businesses, changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its financial and operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures for the three and nine months ended September 30, 2015 and 2014, and for the forecasted three month period and full year ending December 31, 2015, as well as reasons for excluding each of these individual items:

Adjusted Net Income and Adjusted Net Income per Share:

•
Intangibles asset impairment charges - This amount represents non-cash write-downs of certain intangible asset balances in the first nine months of 2015 and 2014. We remove the impact of non-cash impairment charges from our operating performance to assist in assessing our cash generated from operations. We believe this is a critical metric for us in measuring our ability to generate cash and invest in our growth. Therefore, these charges are excluded from management's assessment of operating performance and are also excluded for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance, particularly in terms of liquidity.

•
Acquisition- and divestiture-related net charges (credits) - These adjustments consist of (a) contingent consideration fair value adjustments; (b) gains on previously held investments; (c) purchased and/or funded in-process research and development expenses incurred outside of a business combination; (d) due diligence, other fees and exit costs; and (e) separation costs and gains primarily associated with the sale of our Neurovascular business in January 2011. The contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. Due diligence, other fees and exit costs include legal, tax, severance and other expenses associated with prior and potential future acquisitions and divestitures that can be highly variable and not representative of ongoing operations. Separation costs and gains on the sale of a business unit primarily represent those associated with the Neurovascular divestiture and are not representative of ongoing operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

•
Restructuring and restructuring-related net charges (credits) - These adjustments represent primarily severance and other direct costs associated with our 2014 Restructuring program. These costs are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these costs for purposes of calculating these non-GAAP financial




measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

•
Litigation-related net charges (credits) - These adjustments include certain significant product liability and other litigation-related charges and credits. These amounts are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

•
Debt extinguishment charges - This item represents premiums, accelerated amortization of debt issuance costs and investor discount costs net of interest rate hedge gains related to the early extinguishment of $1.0 billion of public senior notes during the second quarter of 2015. These adjustments are not expected to recur and do not reflect expected ongoing operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

•
Pension termination charges - This item represents charges associated with the termination of the Guidant Retirement Plan, a frozen defined benefit plan. These charges are not expected to recur after 2015 and do not reflect expected ongoing operating results. Accordingly, management has excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

•
Amortization expense - Amortization expense is a non-cash expense and does not impact our liquidity or compliance with the financial covenants included in our credit facility or our term loan facility agreements. Management removes the impact of amortization from our operating performance to assist in assessing our cash generated from operations. We believe this is a critical metric for measuring our ability to generate cash and invest in our growth. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance, particularly in terms of liquidity.

Revenue Growth Rates Excluding the Impact of Sales from Divested Businesses, Changes in Foreign Currency Exchange Rates and/or the Impact of Recent Acquisitions with Significant Sales

•
Sales from divested businesses are primarily associated with the Neurovascular divestiture and are not representative of ongoing operations. The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. The impact of recent acquisitions with significant sales in the current period and no prior period equivalent may distort our presentation of organic growth. Accordingly, management excludes the impact of sales from divested businesses, changes in foreign currency exchange rates and/or the impacts of recent acquisitions with significant sales for purposes of reviewing revenue growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.





Adjusted net income and adjusted net income per share that exclude certain amounts, and revenue growth rates that exclude the impact of sales from divested businesses, changes in foreign currency exchange rates and/or the impacts of recent acquisitions with significant sales, are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.



 GRAPHIC 3 letterheadlogo.jpg begin 644 letterheadlogo.jpg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